# Anika Therapeutics Inc. (ANIK)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $211M  
**Price:** $14.72 (-1.54%)

> Anika Therapeutics Inc. is a joint preservation company specializing in the design, development, manufacturing, and commercialization of hyaluronic acid (HA)-based innovations for orthopedic care. It focuses on early intervention solutions in osteoarthritis pain management, regenerative medicine, sports medicine, and bone-preserving joint solutions, delivered through products like Orthovisc, Monovisc, and Cingal for viscosupplementation injections that provide pain relief and restore joint function. The company also offers regenerative products such as Hyalofast and Tactoset for tissue repair, alongside non-orthopedic offerings including veterinary products like Hyvisc for equine joint issues, anti-adhesion barriers like Hyalobarrier for surgical use, and ophthalmic solutions. Anika Therapeutics Inc. partners with clinicians and distributes its portfolio globally to surgeons, hospitals, and ambulatory surgery centers, emphasizing minimally invasive treatments that delay invasive procedures and promote active living. Founded in 1992 and headquartered in Bedford, Massachusetts, it holds a leading position in HA-based osteoarthritis pain management in the U.S. market.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $113M | $64M | -$11M | -$11M | — |
| 2024 | $120M | $76M | -$5M | -$56M | — |
| 2023 | $121M | $83M | $844,000 | -$83M | — |
| 2022 | $114M | $73M | $4M | -$15M | — |
| 2021 | $148M | $83M | $3M | $4M | — |
| 2020 | $130M | $69M | -$28M | -$24M | — |
| 2019 | $115M | $86M | $34M | $27M | — |
| 2018 | $106M | $74M | $22M | $19M | — |
| 2017 | $113M | $86M | $46M | $32M | — |
| 2016 | $103M | $79M | $51M | $33M | — |
| 2015 | $93M | $72M | $48M | $31M | — |
| 2014 | $106M | $85M | $61M | $38M | — |
| 2013 | $75M | $52M | $33M | $21M | — |
| 2012 | $71M | $42M | $20M | $12M | — |
| 2011 | $65M | $38M | $14M | $8M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $190M | $47M | $143M | $57M | — |
| 2024 | $203M | $49M | $154M | $56M | — |
| 2023 | $271M | $58M | $212M | $69M | — |
| 2022 | $349M | $64M | $286M | $86M | — |
| 2021 | $348M | $60M | $287M | $94M | — |
| 2020 | $366M | $93M | $272M | $96M | — |
| 2019 | $331M | $42M | $288M | $157M | — |
| 2018 | $279M | $15M | $264M | $89M | — |
| 2017 | $283M | $19M | $263M | $133M | — |
| 2016 | $240M | $17M | $223M | $104M | — |
| 2015 | $236M | $25M | $211M | $111M | — |
| 2014 | $193M | $15M | $178M | $100M | — |
| 2013 | $156M | $20M | $136M | $63M | — |
| 2012 | $142M | $33M | $109M | $44M | $10M |
| 2011 | $133M | $38M | $95M | $36M | $13M |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | $11M | $7M | $4M |
| 2024 | $5M | $8M | -$2M |
| 2023 | -$2M | $5M | -$7M |
| 2022 | $4M | $7M | -$3M |
| 2021 | $8M | $5M | $3M |
| 2020 | $13M | $2M | $11M |
| 2019 | $37M | $3M | $34M |
| 2018 | $35M | $5M | $30M |
| 2017 | $41M | $9M | $32M |
| 2016 | $24M | $14M | $10M |
| 2015 | $40M | $9M | $31M |
| 2014 | $40M | $2M | $38M |
| 2013 | $25M | $441,000 | $25M |
| 2012 | $11M | $2M | $9M |
| 2011 | $10M | $1M | $9M |

Source: [CompaniesByCap](https://companiesbycap.com/company/ANIK)